Dr. Schwartz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1190 5th Ave
# Mount
New York, NY 10029Phone+1 212-241-6756Fax+1 212-423-0522
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1996 - 1999
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1992 - 1996
Washington University in St. Louis School of MedicineClass of 1992
Certifications & Licensure
NY State Medical License 1993 - 2025
Publications & Presentations
PubMed
- 45 citationsSystemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon diseaseAna Maria Manso, Sherin Hashem, Bradley C. Nelson, Emily Gault, Angel Soto-Hermida
Science Translational Medicine. 2020-03-18 - 340 citationsRecurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis.Sasan Roayaie, Jonathan D. Schwartz, Max W. Sung, Sukru Emre, Charles M. Miller
Liver Transplantation. 2004-04-01 - 1623 citationsRamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW)...Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, György Bodoky
The Lancet. Oncology. 2014-10-01
Abstracts/Posters
- Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene...Jonathan D Schwartz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Hematopoietic Engraftment of Fanconi Anemia Patients through 3 Years after Gene TherapyJonathan D Schwartz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-IDecember 9th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
